Aridhia's Data Platform Chosen for Alzheimer's Research Project
News Nov 06, 2015
Aridhia has announced that their AnalytiXagility data platform has been chosen to underpin a three year research programme that was awarded Innovate UK funding via the Neurodegenerative Diseases: Business Models and Big Data competition, following a joint bid by three of Northern Ireland’s leading organizations.
The resulting Moneta Research project – led by Asystec Data Solutions, the University of Ulster and the Clinical Translational Research and Innovation Centre (C-TRIC) – will use the funding to support their research into identifying people most likely to develop Alzheimer’s.
The collaborative project will apply ‘beyond’ computational analysis and modelling to a large biological and clinical dataset of Alzheimer’s patients, and will bring together clinical research skills from the across the University and C-TRIC with analytics expertise from Asystec to collaboratively build predictive models that can be used to estimate the likely probability of currently healthy patients developing a major neurodegenerative disorder like Alzheimer’s.
Chris Roche, CEO at Aridhia said, “We are delighted that the collaboration have chosen AnalytiXagility as the platform for Moneta Research. Asystec have made great strides in the last twelve months with the data services they offer. Winning this award in collaboration with the University of Ulster, in such an important area of research, is a real boost for Northern Ireland and demonstrates Asystec’s continued leadership in bringing data innovation to Ireland.”
The project will utilize the new functional brain mapping facility at the University of Ulster to create an enhanced dataset, based on imaging data, which can then be utilized to increase the accuracy of the predictive model.
Working with such datasets requires a cutting-edge data platform and Aridhia are delighted that AnalytiXagility has been chosen to enable the collaborative analysis of the project’s large complex and heterogeneous datasets, which include demographics, medical history, neuropsychology scores, blood analysis, diagnosis, and neuroimaging data.
Dave Clarke, Chief Data Scientist, at Asystec said, “A big challenge for Alzheimer’s research is the integration and analysis of big heterogenous data to holistically understand the disease and the stratification of treatments. We’ve worked with Aridhia for over a year now and their focus on building a platform that supports collaborative clinical and healthcare research made AnalytiXagility an easy choice for us when selecting a partner to work with.”
The hope is that, by through linking among different biomarkers, the resulting predictive models might reveal new disease signatures, relationships and treatments, and encourage a move towards early identification of risk of developing Alzheimer’s disease.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Deceased Data: Should Your Online Remains Be Treated Like Physical Remains?News
In 2018, your death doesn't just leave behind a body. It leaves behind a huge online footprint - your digital remains. A new study asks whether these remains should be treated and respected as a corpse would, and whether museums may provide a blueprint for the preservation process.READ MORE